JP2015521643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521643A5 JP2015521643A5 JP2015519035A JP2015519035A JP2015521643A5 JP 2015521643 A5 JP2015521643 A5 JP 2015521643A5 JP 2015519035 A JP2015519035 A JP 2015519035A JP 2015519035 A JP2015519035 A JP 2015519035A JP 2015521643 A5 JP2015521643 A5 JP 2015521643A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- disorder
- disease
- pharmaceutically acceptable
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims 11
- 230000036407 pain Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 230000036541 health Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical class C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- VQVLEDQDCNRDNQ-UHFFFAOYSA-N 6-[[5-(difluoromethyl)-3-(4-fluorophenyl)triazol-4-yl]methoxy]pyridazine-3-carboxamide Chemical compound N1=NC(C(=O)N)=CC=C1OCC1=C(C(F)F)N=NN1C1=CC=C(F)C=C1 VQVLEDQDCNRDNQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010072132 Fracture pain Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664288P | 2012-06-26 | 2012-06-26 | |
| US61/664,288 | 2012-06-26 | ||
| DKPA201270369 | 2012-06-26 | ||
| DKPA201270369 | 2012-06-26 | ||
| PCT/EP2013/063194 WO2014001282A1 (en) | 2012-06-26 | 2013-06-25 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521643A JP2015521643A (ja) | 2015-07-30 |
| JP2015521643A5 true JP2015521643A5 (https=) | 2016-08-12 |
| JP6223443B2 JP6223443B2 (ja) | 2017-11-01 |
Family
ID=49782300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519035A Expired - Fee Related JP6223443B2 (ja) | 2012-06-26 | 2013-06-25 | フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9475797B2 (https=) |
| EP (1) | EP2885290B1 (https=) |
| JP (1) | JP6223443B2 (https=) |
| KR (1) | KR20150033679A (https=) |
| CN (1) | CN104411703A (https=) |
| AU (1) | AU2013283488A1 (https=) |
| BR (1) | BR112014032501A2 (https=) |
| CA (1) | CA2876780A1 (https=) |
| IL (1) | IL235991A (https=) |
| IN (1) | IN2014DN11027A (https=) |
| MX (1) | MX2014014872A (https=) |
| RU (1) | RU2014149123A (https=) |
| WO (1) | WO2014001282A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| CN115461337A (zh) * | 2020-05-13 | 2022-12-09 | 豪夫迈·罗氏有限公司 | 作为GABA A α5 PAM的新型三唑基衍生物 |
| US20230286946A1 (en) * | 2020-08-05 | 2023-09-14 | Boehringer Ingelheim International Gmbh | Difluoromethyl-pyridin-2-yl triazoles |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN116462664B (zh) * | 2022-03-08 | 2025-07-01 | 上海赛默罗生物科技有限公司 | 吡唑环类化合物、其制备方法、组合物及应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7296896A (en) | 1995-11-01 | 1997-05-22 | Novartis Ag | Purine derivatives and processes for their preparation |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| EP1042299A1 (en) | 1997-12-22 | 2000-10-11 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| JP2003531111A (ja) | 1999-12-17 | 2003-10-21 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | プロトンポンプインヒビター |
| ATE327242T1 (de) | 1999-12-17 | 2006-06-15 | Ariad Pharma Inc | Neue purine |
| DE60031886T2 (de) | 1999-12-17 | 2007-09-06 | Ariad Pharmaceuticals, Inc., Cambridge | Purinderivate |
| DE60205376T2 (de) | 2001-06-27 | 2006-04-06 | Cyclacel Ltd. | 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten |
| US7262176B2 (en) | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| EP1578722A4 (en) | 2001-10-12 | 2006-09-06 | Irm Llc | KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF |
| US20030229105A1 (en) | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| MXPA06001758A (es) | 2003-08-15 | 2006-08-11 | Irm Llc | Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk. |
| US20050239806A1 (en) | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| GB0407723D0 (en) | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| FR2876583B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0505219D0 (en) | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
| WO2006097441A1 (en) | 2005-03-14 | 2006-09-21 | Neurosearch A/S | Potassium channel modulating agents and their medical use |
| US20090036475A1 (en) | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| US7514417B2 (en) | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| EP1931661B1 (en) | 2005-09-19 | 2008-11-19 | F.Hoffmann-La Roche Ag | Isoxazolo derivatives as gaba a alpha5 inverse agonists |
| WO2007042420A1 (en) | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Isoxazole derivatives |
| KR101103129B1 (ko) | 2005-11-09 | 2012-01-04 | 에프. 호프만-라 로슈 아게 | 3-아릴-아이속사졸-4-카본일-벤조퓨란 유도체 |
| EP1966184B1 (en) | 2005-12-20 | 2010-08-25 | NeuroSearch A/S | Pyridinyl-quinazoline derivatives and their medical use |
| RU2426731C2 (ru) | 2005-12-23 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | Производные арил-изоксазоло-4-ил-оксадиазола |
| JP4864982B2 (ja) | 2005-12-27 | 2012-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体 |
| BRPI0620773A2 (pt) | 2005-12-27 | 2011-11-22 | Hoffmann La Roche | derivados de aril-isoxazol-4-il-imidazol |
| US8106077B2 (en) * | 2006-05-24 | 2012-01-31 | Eli Lilly And Company | Compounds and methods for modulating FXR |
| MX2008014796A (es) | 2006-05-31 | 2008-12-02 | Hoffmann La Roche | Derivados de aril-4-etinil-isoxazol. |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| US20110144140A1 (en) | 2006-09-07 | 2011-06-16 | Eriksen Birgitte L | Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
| JP2010505794A (ja) | 2006-10-03 | 2010-02-25 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル調節剤として有用なインダゾリル誘導体 |
| KR20090112732A (ko) | 2007-01-26 | 2009-10-28 | 아이알엠 엘엘씨 | 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물 |
| EP2114916A2 (en) | 2007-02-02 | 2009-11-11 | NeuroSearch A/S | Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| EP2144911A2 (en) | 2007-03-28 | 2010-01-20 | NeuroSearch AS | Purinyl derivatives and their use as potassium channel modulators |
| KR101564233B1 (ko) | 2007-03-28 | 2015-10-29 | 뉴로서치 에이/에스 | 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도 |
| JP5416103B2 (ja) | 2007-06-22 | 2014-02-12 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾール−イミダゾール誘導体 |
| BRPI0818578A2 (pt) | 2007-10-17 | 2015-07-21 | Novartis Ag | Derivados de purina como ligantes receptores de adenosina a1 |
| UA100132C2 (en) | 2007-12-04 | 2012-11-26 | Ф. Хоффманн-Ля Рош Аг | Isoxazolo-pyridine derivatives |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| WO2009071464A1 (en) | 2007-12-04 | 2009-06-11 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| NZ600238A (en) * | 2008-06-19 | 2014-04-30 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
| US20110237607A1 (en) | 2008-09-26 | 2011-09-29 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| US8268838B2 (en) | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US8227461B2 (en) | 2009-04-30 | 2012-07-24 | Hoffmann-La Roche Inc. | Isoxazoles |
| AU2010244552A1 (en) | 2009-05-05 | 2011-09-29 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| WO2010127976A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| EP2427458B1 (en) * | 2009-05-05 | 2014-05-07 | F.Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| MX2011011490A (es) | 2009-05-05 | 2011-11-18 | Hoffmann La Roche | Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos. |
| MX2011011484A (es) | 2009-05-07 | 2011-11-18 | Hoffmann La Roche | Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico. |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP2638035B1 (en) * | 2010-11-09 | 2014-12-17 | F.Hoffmann-La Roche Ag | Triazole derivatives as ligands for Gaba receptors |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US8466181B2 (en) | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
-
2013
- 2013-06-25 US US14/411,326 patent/US9475797B2/en not_active Expired - Fee Related
- 2013-06-25 JP JP2015519035A patent/JP6223443B2/ja not_active Expired - Fee Related
- 2013-06-25 KR KR20157001895A patent/KR20150033679A/ko not_active Withdrawn
- 2013-06-25 CN CN201380034072.1A patent/CN104411703A/zh active Pending
- 2013-06-25 BR BR112014032501A patent/BR112014032501A2/pt not_active IP Right Cessation
- 2013-06-25 CA CA2876780A patent/CA2876780A1/en not_active Abandoned
- 2013-06-25 RU RU2014149123A patent/RU2014149123A/ru not_active Application Discontinuation
- 2013-06-25 EP EP13730899.5A patent/EP2885290B1/en not_active Not-in-force
- 2013-06-25 IN IN11027DEN2014 patent/IN2014DN11027A/en unknown
- 2013-06-25 AU AU2013283488A patent/AU2013283488A1/en not_active Abandoned
- 2013-06-25 WO PCT/EP2013/063194 patent/WO2014001282A1/en not_active Ceased
- 2013-06-25 MX MX2014014872A patent/MX2014014872A/es unknown
-
2014
- 2014-11-30 IL IL235991A patent/IL235991A/en not_active IP Right Cessation
-
2016
- 2016-10-11 US US15/290,480 patent/US9884848B2/en not_active Expired - Fee Related